Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Sarvajit Chakravarty"'
Autor:
Brahmam Pujala, Sreekanth A. Ramachandran, Mukesh Sonawane, Maruti M. Kamble, Dayanand Panpatil, Swati Adhikari, Sanjeev Soni, Venkata Subbareddy, Bharat U. Shinde, Anjan K. Nayak, Chandni Bansal, Ashu Gupta, Kakoli Mukherjee, Anil K. Agarwal, Javier Guerrero, Francisco J. Herrera, Sebastian Bernales, Mausumee Guha, Sarvajit Chakravarty, Son M. Pham, Roopa Rai
Publikováno v:
Bioorganicmedicinal chemistry letters. 75
Compound 1 is a potent TGF-β receptor type-1 (TGFβR1 or ALK5) inhibitor but is metabolically unstable. A solvent-exposed part of this molecule was used to analogue and modulate cell activity, liver microsome stability and mouse pharmacokinetics. Th
Autor:
Sreekanth A. Ramachandran, Anil K. Agarwal, Maruti M. Kamble, Brahmam Pujala, Ratnesh Sharma, Manvendra Singh, Bharat U. Shinde, Dayanand Panpatil, Ashu Gupta, Kakoli Mukherjee, Srijan Haldar, Chandni Bansal, Roopa Rai, Sarvajit Chakravarty, Son M. Pham
Publikováno v:
SSRN Electronic Journal.
Autor:
Brahmam Pujala, Balaji Dashrath Sathe, Ashu Gupta, Abhinandan Danodia, Sanjeev Soni, Vivek Kumar, Uzma Saeed, Sarvajit Chakravarty
Publikováno v:
Cancer Research. 82:5465-5465
Nuclear receptors, liver X receptor-α (LXRα) and liver X receptor-β (LXRβ), are considered master regulators of lipid homeostasis and play pivotal roles in several physiological and pathological processes ranging from energy supply, cardiovascula
Autor:
Ashu Gupta, Son Minh Pham, Ramachandran Sreekanth A, Sebastian Belmar, Francisco J. Herrera, Iván E. Alfaro, Mohd. Raja, Pradeep S. Jadhavar, Anil Agarwal, Deepak P. Kalane, Sebastian Bernales, Siddhartha Singh, Kakoli Mukherjee, Kevin P. Quinn, Sathe Balaji Dashrath, Roopa Rai, Sandeep K. Miglani, Christopher Higgs, Srijan Haldar, Manvendra Singh, Sarvajit Chakravarty
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:2153-2160
Signaling via the receptor tyrosine kinase CSF1R is thought to play an important role in recruitment and differentiation of tumor-associated macrophages (TAMs). TAMs play pro-tumorigenic roles, including the suppression of anti-tumor immune response,
Autor:
Luz Delgado, Roopa Rai, Shailender Chauhan, Patricio Avila, Dhananjay I. Patel, Glenda Fuentealba, Camila Flores, Kevin P. Quinn, T. V. R. Upendra, Vijay Kumar Sharma, Sarvajit Chakravarty, Anjan Kumar Nayak, Emma McCullagh, Gonzalo Ureta, Ramona Almirez, Brahmam Pujala, Sebastian Bernales, Jennifer Alfaro, David T. Hung, Son Minh Pham, Diana Gaete, Sebastian Belmar, Felipe Pérez de Arce, Stacy Kanno, Claudia Acuña, Anup Barde
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 361:312-321
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eve
Autor:
Sharad Satalkar, Roopa Rai, Amantullah Ansari, A. K. Gupta, Shete Amit, Francisco J. Herrera, Sebastian Bernales, Patil Varshavekumar S, Mohd. Raja, Siddhartha Singh, Simranjeet Kaur, Son Minh Pham, David T. Hung, Daniel L. Severance, Sarvajit Chakravarty
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:217-222
EZH2 (enhancer of zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27). Dysregulation of EZH2 activity is associated with several human cancers and t
Autor:
Michael J. Green, Roopa Rai, Kevin P. Quinn, Ashu Gupta, Jennifer Alfaro, Dhananjay I. Patel, David T. Hung, Stacy Kanno, Nitin Atmaram Randive, Emma McCullagh, Monali Banerjee, Anamika Thakur, Sarvajit Chakravarty, Anjan Kumar Nayak, Anil Agarwal, Ramona Almirez, Sweta Khare, Brahmam Pujala, Rambabu Guguloth, Sebastian Bernales, Sandip Middya, Mohd. Raja, Son Minh Pham, Bharat Uttam Shinde, Felipe Pérez de Arce, Arjun Surya, Patricio Avila
Publikováno v:
ACS Medicinal Chemistry Letters. 7:1161-1166
The aberrant activation of B-cells has been implicated in several types of cancers and hematological disorders. BTK and PI3Kδ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clinical benefit
Autor:
Jennifer, Alfaro, Felipe, Pérez de Arce, Sebastián, Belmar, Glenda, Fuentealba, Patricio, Avila, Gonzalo, Ureta, Camila, Flores, Claudia, Acuña, Luz, Delgado, Diana, Gaete, Brahmam, Pujala, Anup, Barde, Anjan K, Nayak, T V R, Upendra, Dhananjay, Patel, Shailender, Chauhan, Vijay K, Sharma, Stacy, Kanno, Ramona G, Almirez, David T, Hung, Sarvajit, Chakravarty, Roopa, Rai, Sebastián, Bernales, Kevin P, Quinn, Son M, Pham, Emma, McCullagh
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eve
Autor:
David T. Hung, Roopa Rai, Jeffrey N. Lindquist, Iván E. Alfaro, Ramachandran Sreekanth A, Kevin P. Quinn, Devleena Shivakumar, Eduardo Riquelme, Sebastian Belmar, Soumya S. Ray, Sarvajit Chakravarty, Anjan Kumar Nayak, Sathe Balaji Dashrath, Pradeep S. Jadhavar, Dnyaneshwar Zende, Javier Sanchez Guerrero, Ashu Gupta, Sebastian Bernales, Sandeep K. Miglani, Mohd. Raja, Olivia Farias
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(21)
While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20-40% of patients have no response to these agents. It has been stipulated that the lack of response and the deve
Autor:
Sandip Middya, Monali Banerjee, Eduardo Riquelme, Sarvajit Chakravarty, Pankaj Melkani, Vikas Dixit, Felipe Olivares, Shyamraj Yadav, Umesh K. Patil, David T. Hung, Andrew A. Protter, Shailendra Tripathi, Roopa Rai, Javier Sanchez Guerrero, Ashu Gupta, Emma McCullagh, Darren H. Wong, Sebastian Bernales, Ramnivas Jangir, Arjun Surya, Son Minh Pham, Ritesh Shrivastava, Mohd. Raja
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(20)
Temozolomide is a chemotherapeutic agent that is used in the treatment of glioblastoma and other malignant gliomas. It acts through DNA alkylation, but treatment is limited by its systemic toxicity and neutralization of DNA alkylation by upregulation